In the aftermath of President Trump’s sweeping election victory, Big Pharma is reportedly on high alert, with top executives in the industry scrambling to prepare for what could be a seismic shift in U.S. healthcare policy. According to insider reports, CEOs from the five biggest pharmaceutical companies dialed into an emergency teleconference Wednesday afternoon, fearing what Trump’s return to the White House could mean for their stranglehold on healthcare.
New Jersey Assemblyman Jamel Holley, an advisor to Robert Kennedy Jr., took to social media to break the news, stating, “Sources tell me top five CEOs of pharmaceutical companies are holding an emergency teleconference at 1 PM. A lawyer has confirmed that everyone is in a state of panic!” And why wouldn’t they be? For an industry that’s made billions off the backs of hardworking Americans, a Trump-Kennedy duo threatens to turn off the money faucet they’ve come to rely on.
Sources tell me top five CEOs of pharmaceutical companies are holding an emergency teleconference at 1 PM.
A lawyer has confirmed that everyone is in a state of panic!
— Jamel Holley (@jamelholley) November 6, 2024
With Kennedy—a longtime critic of corporate meddling in health policy—slated for a top role in overhauling the FDA and CDC, it’s no surprise that Big Pharma is sweating bullets. Kennedy has been vocal about his commitment to restoring the integrity of federal health agencies by putting the interests of the American people above corporate profits. Holley even joked online, “If RFK Jr. asks me which meeting I’d like to attend, I’ll politely say the one with you & Bill Gates.” Gates and his pals in Big Pharma might want to start packing now because a health policy shakeup is coming.
At the Financial Times Global Pharma and Biotech Summit in London, GSK CEO Emma Walmsley tried to strike a diplomatic tone, noting, “The U.S. is extremely important to GSK…more than half of the business is in the U.S.” In other words, they’re a little too comfortable with the billions in revenue generated by American customers. Walmsley continued, saying, “Let’s see what happens in terms of who is appointed into what kind of role in the administration.” Translation: Big Pharma is nervously eyeing Trump’s appointments, knowing full well that their days of unchecked influence may be numbered.
President Trump has asked me to do three things:
1. Clean up the corruption in our government health agencies.
2. Return those agencies to their rich tradition of gold-standard, evidence-based science.
3. Make America Healthy Again by ending the chronic disease epidemic. pic.twitter.com/WHMOsD0CiI— Robert F. Kennedy Jr (@RobertKennedyJr) November 6, 2024
Trump’s choice of Kennedy as a possible reform leader is a nightmare scenario for these pharmaceutical executives. GSK and other pharma giants have invested heavily in the vaccine market—no surprise there—but they know that Kennedy’s mission is to expose any practice that puts profits over public health. When asked about Kennedy’s “Make America Healthy Again” mantra, Walmsley remarked, “Actually, making America healthy again is a really good idea.” Imagine that—Big Pharma finally admitting America’s health matters. Perhaps the rest of the industry can get the memo.
For the American public, this could be the beginning of a new era in healthcare—one where Big Pharma doesn’t get to dictate policy behind closed doors. It’s about time a government stood up for the citizens instead of catering to corporate giants. This election win signals a new chapter, one where accountability comes first, and Big Pharma’s unchecked influence comes to a screeching halt. The American people voted for change, and they’re finally getting it.
